{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:35:56Z","timestamp":1793144156224,"version":"4.5.0"},"reference-count":59,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyse drug-associated immune-mediated uveitis (IMU) risk using large-scale pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance study using data from the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) databases, encompassing reports from Q1 2004 to Q4 2024. Disproportionality analysis identified drug-IMU associations using reporting odds ratios (ROR) and information component (IC). Time-to-onset (TTO) was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Disproportionality analysis identified 17\u2009176 IMU cases in FAERS and 2580 in JADER. IMU prevalence was higher in females, with the 30\u201380 age group most affected. Antineoplastic and immunomodulating agents, sensory organ drugs and anti-infectives were the most frequently associated drug classes with IMU. Among 117 drugs with positive signals for IMU in FAERS, brolucizumab (ROR\n                      <jats:sub>025<\/jats:sub>\n                      =145.89, IC\n                      <jats:sub>025<\/jats:sub>\n                      =7.08), faricimab (ROR\n                      <jats:sub>025<\/jats:sub>\n                      =134.06, IC\n                      <jats:sub>025<\/jats:sub>\n                      =6.97) and rifabutin (ROR\n                      <jats:sub>025<\/jats:sub>\n                      =82.23, IC\n                      <jats:sub>025<\/jats:sub>\n                      =6.32) exhibited the strongest associations. The three drugs also ranked as the top three drugs with the strongest association with IMU in JADER. The study also highlights significant differences in TTO among various drug classes, with musculoskeletal and sensory organ drugs showing longer TTO compared with other categories.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study highlights the diverse range of drugs implicated in the occurrence or progression of IMU. These findings emphasise the need for early risk assessment, careful monitoring and positive intervention in managing treatments involving high-risk drugs. Future research should focus on elucidating underlying mechanisms and risk factors to develop safer therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002456","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:41:44Z","timestamp":1764333704000},"page":"e002456","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-3860","authenticated-orcid":false,"given":"Shanshan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1539-1705","authenticated-orcid":false,"given":"Yiman","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ente","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2025112804413414000_10.1.e002456.1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000518496","article-title":"Immune-Mediated Uveitis and Lifestyle Factors: A Review","volume":"64","author":"Guo","year":"2021","journal-title":"Ophthalmic Res"},{"key":"2025112804413414000_10.1.e002456.2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of Noninfectious Uveitis in the United States","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2025112804413414000_10.1.e002456.3","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_816_20"},{"key":"2025112804413414000_10.1.e002456.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-022-00168-6"},{"key":"2025112804413414000_10.1.e002456.5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/1346-8138.17082","article-title":"Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF\/MEK inhibitors in melanoma patients with HLA-DRB1*04","volume":"51","author":"Amagai","year":"2024","journal-title":"J Dermatol"},{"key":"2025112804413414000_10.1.e002456.6","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199717030-00005"},{"key":"2025112804413414000_10.1.e002456.7","first-page":"83","article-title":"Drug-induced ocular inflammation","volume":"133","author":"Samalia","year":"2020","journal-title":"N Z Med J"},{"key":"2025112804413414000_10.1.e002456.8","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315280"},{"key":"2025112804413414000_10.1.e002456.9","first-page":"785","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology (Los Angel)"},{"key":"2025112804413414000_10.1.e002456.10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025112804413414000_10.1.e002456.11","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025112804413414000_10.1.e002456.12","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241260211","article-title":"Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System","volume":"15","author":"Ouyang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"2025112804413414000_10.1.e002456.13","doi-asserted-by":"crossref","first-page":"1392914","DOI":"10.3389\/fphar.2024.1392914","article-title":"A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases","volume":"15","author":"Zou","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025112804413414000_10.1.e002456.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06611-y"},{"key":"2025112804413414000_10.1.e002456.15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2025112804413414000_10.1.e002456.16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508"},{"key":"2025112804413414000_10.1.e002456.17","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403604"},{"key":"2025112804413414000_10.1.e002456.18","doi-asserted-by":"crossref","first-page":"767987","DOI":"10.3389\/fcvm.2022.767987","article-title":"Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study","volume":"9","author":"Zhai","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025112804413414000_10.1.e002456.19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14740338.2023.2251382","article-title":"Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"23","author":"Zou","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2025112804413414000_10.1.e002456.20","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5032881","article-title":"Describing the Clinical and Laboratory Features and HLA-B Pattern of Adult-Onset Idiopathic Autoimmune Uveitis at a Tertiary Hospital in South India: A Cross-Sectional Study","volume":"2022","author":"Visalakshy","year":"2022","journal-title":"ScientificWorldJournal"},{"key":"2025112804413414000_10.1.e002456.21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.59204\/2314-6788.3258","article-title":"Epidemiology and Clinical Features of Immune Mediated Uveitis in Menoufia population","volume":"37","author":"Zahran","year":"2024","journal-title":"Menoufia Medical Journal"},{"key":"2025112804413414000_10.1.e002456.22","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1255761"},{"key":"2025112804413414000_10.1.e002456.23","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.31936"},{"key":"2025112804413414000_10.1.e002456.24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/09273948.2016.1196714","article-title":"Demographic and Clinical Characteristics of Uveitis in Turkey: The First National Registry Report","volume":"26","author":"Yal\u00e7\u0131nda\u011f","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2025112804413414000_10.1.e002456.25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/CMR.0000000000000933","article-title":"Uveitis associated with immune checkpoint inhibitors or BRAF\/MEK inhibitors in patients with malignant melanoma","volume":"33","author":"Sada","year":"2023","journal-title":"Melanoma Res"},{"key":"2025112804413414000_10.1.e002456.26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2024.07.002","article-title":"Real\u2010World Incidence of Incident Noninfectious Uveitis in Patients Treated With BRAF Inhibitors: A Nationwide Clinical Cohort Study","volume":"267","author":"Jung","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"2025112804413414000_10.1.e002456.27","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025112804413414000_10.1.e002456.28","doi-asserted-by":"crossref","first-page":"1556313","DOI":"10.3389\/fimmu.2025.1556313","article-title":"Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"2025112804413414000_10.1.e002456.29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025112804413414000_10.1.e002456.30","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30008-4"},{"key":"2025112804413414000_10.1.e002456.31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025112804413414000_10.1.e002456.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2025112804413414000_10.1.e002456.33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/eye.1994.181","article-title":"Betaxolol-associated anterior uveitis","volume":"8 (Pt 6)","author":"Jain","year":"1994","journal-title":"Eye (Lond)"},{"key":"2025112804413414000_10.1.e002456.34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/09273940590928562","article-title":"Steroid Hypopyon Following Intravitreal Triamcinolone Acetonide Injection in a Pseudophakic Patient","volume":"13","author":"Amato","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"2025112804413414000_10.1.e002456.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2025112804413414000_10.1.e002456.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"2025112804413414000_10.1.e002456.37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/ICB.0b013e3182964f7c","article-title":"Sequential, acute noninfectious uveitis associated with separate intravitreal injections of bevacizumab and ranibizumab","volume":"7","author":"Cunningham","year":"2013","journal-title":"Retin Cases Brief Rep"},{"key":"2025112804413414000_10.1.e002456.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"2025112804413414000_10.1.e002456.39","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.75.9.519"},{"key":"2025112804413414000_10.1.e002456.40","unstructured":"Hondeghem K , Augustinus B , De Smet MD . Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports. Bull Soc Belge Ophtalmol 2009;51\u20132."},{"key":"2025112804413414000_10.1.e002456.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0886-3350(03)00470-X"},{"key":"2025112804413414000_10.1.e002456.42","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181132188"},{"key":"2025112804413414000_10.1.e002456.43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.exer.2012.11.003","article-title":"Pilocarpine-induced flare is physiological rather than pathological","volume":"107","author":"Freddo","year":"2013","journal-title":"Exp Eye Res"},{"key":"2025112804413414000_10.1.e002456.44","article-title":"Travoprost induced granulomatous anterior uveitis","volume":"2011","author":"Chiam","year":"2011","journal-title":"Case Rep Ophthalmol Med"},{"key":"2025112804413414000_10.1.e002456.45","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"2025112804413414000_10.1.e002456.46","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/09273948.2023.2293925","article-title":"Uveitis Following Intravitreal Injections of Faricimab: A Case Report","volume":"32","author":"Palmieri","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"2025112804413414000_10.1.e002456.47","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"2025112804413414000_10.1.e002456.48","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025112804413414000_10.1.e002456.49","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","article-title":"Drug-induced uveitis","volume":"29","author":"Moorthy","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"2025112804413414000_10.1.e002456.50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ogla.2024.10.010","article-title":"Incidence of Uveitis Following Initiation of Prostaglandin Analogs versus Other Glaucoma Medications: A Study from the Sight Outcomes Research Collaborative Repository","volume":"8","author":"Chauhan","year":"2025","journal-title":"Ophthalmol Glaucoma"},{"key":"2025112804413414000_10.1.e002456.51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1076\/ocii.7.3.223.3999","article-title":"Uveitis in patients treated with intravenous cidofovir","volume":"7","author":"Cochereau","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"key":"2025112804413414000_10.1.e002456.52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jamaophthalmol.2015.4092","article-title":"Oral Fluoroquinolones and the Risk of Uveitis","volume":"134","author":"Sandhu","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2025112804413414000_10.1.e002456.53","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.eye.6702483","article-title":"Bilateral acute anterior uveitis as a side effect of trimethoprim","volume":"21","author":"Pathak","year":"2007","journal-title":"Eye (Lond)"},{"key":"2025112804413414000_10.1.e002456.54","doi-asserted-by":"publisher","DOI":"10.1086\/517366"},{"key":"2025112804413414000_10.1.e002456.55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jop.2022.0094","article-title":"Ocular Side Effects of Bisphosphonates: A Review of Literature","volume":"39","author":"Chartrand","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025112804413414000_10.1.e002456.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02665.x"},{"key":"2025112804413414000_10.1.e002456.57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/OPTO.S492202","article-title":"Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications","volume":"17","author":"Lu","year":"2025","journal-title":"Clin Optom (Auckl)"},{"key":"2025112804413414000_10.1.e002456.58","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"2025112804413414000_10.1.e002456.59","doi-asserted-by":"crossref","first-page":"177820","DOI":"10.1016\/j.ejphar.2025.177820","article-title":"Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database","volume":"1002","author":"Wu","year":"2025","journal-title":"Eur J Pharmacol"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:41:51Z","timestamp":1764333711000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjophth-2025-002456"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002456","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}